You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

80 Results
Guidelines and Advice
Status: Current
ID: 8-6
Version: 2
Aug 2018
Guidelines and Advice
Status: Current
ID: C50-CIDAP-1
Mar 2024
Guidelines and Advice
Status: Current
ID: 8-8
Version: 2
Sep 2025
Regimen
Cancer Type:
Skin, 
Basal Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vismodegib - Treatment for metastatic basal cell carcinoma (BCC) or with locally advanced BCC (including patients with basal cell nevus syndrome, i.e. Gorlin syndrome), according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
vismodegib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Guidelines and Advice
Status: Current
ID: 8-2
Version: 2
Nov 2017
Guidelines and Advice
Status: Current
ID: 8-1
Version: 6
Mar 2024
Guidelines and Advice
Status: Current
ID: GL 8-11
Jan 2018
Guidelines and Advice
Status: Current
ID: 8-7
Version: 2
Mar 2023
Guidelines and Advice
Status: In-Review
ID: 19-6
Apr 2016
Guidelines and Advice
Status: Current
ID: PET 3
Jan 2009
Guidelines and Advice
Status: Archived
ID: 21-3-9
Oct 2010
Guidelines and Advice
Status: Archived
ID: 8-3
Sep 2011

Pages